Non‐small cell lung cancer (NSCLC), which accounts for ~ 80–85% of all lung cancer cases, exhibits mutations, or copy number alterations in NFE2L2/NRF2 or its degradation machinery (KEAP1, CUL3, or RBX1) in > 30% of NSCLC cell lines and patient tissues [5, 6]. Here, NFE2L2 is linked to non-small cell lung carcinoma.